These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 17129811)
1. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies. Van Assche G; Vermeire S; Rutgeerts P Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811 [TBL] [Abstract][Full Text] [Related]
2. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Barrie A; Plevy S Gastroenterol Clin North Am; 2006 Dec; 35(4):883-93. PubMed ID: 17129819 [TBL] [Abstract][Full Text] [Related]
3. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. Nakamura K; Honda K; Mizutani T; Akiho H; Harada N World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430 [TBL] [Abstract][Full Text] [Related]
4. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Van Assche G; Rutgeerts P Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604 [TBL] [Abstract][Full Text] [Related]
12. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Vermeire S; Van Assche G; Rutgeerts P Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190 [TBL] [Abstract][Full Text] [Related]
13. New cytokine therapeutics for inflammatory bowel disease. Stokkers PC; Hommes DW Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691 [TBL] [Abstract][Full Text] [Related]
14. The immune response in inflammatory bowel disease. Brown SJ; Mayer L Am J Gastroenterol; 2007 Sep; 102(9):2058-69. PubMed ID: 17561966 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis. Siegmund B; Zeitz M Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310 [TBL] [Abstract][Full Text] [Related]
17. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Dharmani P; Chadee K Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434 [TBL] [Abstract][Full Text] [Related]
18. Apoptosis as a therapeutic tool in IBD? Lügering A; Lebiedz P; Koch S; Kucharzik T Ann N Y Acad Sci; 2006 Aug; 1072():62-77. PubMed ID: 17057191 [TBL] [Abstract][Full Text] [Related]
19. Celiac disease: from pathogenesis to novel therapies. Schuppan D; Junker Y; Barisani D Gastroenterology; 2009 Dec; 137(6):1912-33. PubMed ID: 19766641 [TBL] [Abstract][Full Text] [Related]
20. Adverse effects of biologics used for treating IBD. Stallmach A; Hagel S; Bruns T Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]